Xspray Pharma AB (XSPRAY) Stock Statistics & Valuation Metrics

Xspray Pharma AB has a market cap or net worth of kr1.22B. The enterprise value is kr1.23B.

Xspray Pharma AB has 47,416,573 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xspray Pharma AB’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -21.48%.

The current PE Ratio of Xspray Pharma AB is ―. Xspray Pharma AB’s PEG ratio is 0.15.

In the last 12 months, Xspray Pharma AB had revenue of 0.00 and earned -171.44M in profits. Earnings per share was -4.46.

In the last 12 months, operating cash flow was -157.51M and capital expenditures -7.20M, giving a free cash flow of -164.71M billion.

Xspray Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xspray Pharma AB upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).

Xspray Pharma AB as a current ratio of 8.44, with Debt / Equity ratio of 25.97%

In the past 12 months, Xspray Pharma AB has paid -104.00K in taxes.

Xspray Pharma AB EV to EBITDA ratio is -7.84, with an EV/FCF ratio of -6.35.

Xspray Pharma AB has kr120.72M in cash and marketable securities with kr147.85M in debt, giving a net cash position of -kr27.13M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Xspray Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―